Skip to main content
. 2022 Mar 29;4(5):e329–e337. doi: 10.1016/S2665-9913(22)00064-9

Figure 1.

Figure 1

ELISA of IL-1Ra antibodies in patients with MIS-C and control participants.

(A) ELISA data for anti-IL-1Ra antibodies in plasma from an exemplary 13 patients with MIS-C. Data for the other eight patients with MIS-C are shown in the appendix (pp 5, 19). Anti-IL-1Ra antibody subclasses in follow-up samples (initial presentation and 3-month and 7-month follow-up) of a single patient (B) and in samples collected at presentation of acute inflammation (C). (D) Titres of anti-IL-1Ra antibodies in patients with MIS-C at presentation. (E) Epitope mapping of anti-IL-1Ra antibodies in MIS-C. (F) ELISA of anti-IL-1Ra antibodies in plasma of intravenous immunoglobulin-naive patients with Kawasaki disease at presentation (n=6) and serum samples obtained from patients with systemic juvenile idiopathic arthritis (in remission; n=10). Positive control was anti-FLAG antibody; negative control was healthy paediatric control plasma. MIS-C=multisystem inflammatory syndrome in children. IL-1Ra=interleukin-1 receptor antagonist. OD=optical density. IL-36Ra=interleukin-36 receptor antagonist. AA=amino acid. sJIA=systemic juvenile idiopathic arthritis. KD=Kawasaki disease.